The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10501472 B1

PDF
Full Text
Expired
Date of Patent:
Dec. 10, 2019

Filed:

Nov. 23, 2015
Applicants:

University of Colombo, Colombo, LK;

National Research Council, Colombo, LK;

Inventors:

Dilusha Fernando, Bandaragama, LK;

Ravi Wijesundera, Maharagama, LK;

Preethi Soysa, Colombo, LK;

Dilip de Silva, Moratuwa, LK;

Chandrika Nanayakkara, Pannipitiya, LK;

Achyut Adhikari, Kathmandu, NP;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 493/20 (2006.01); A61K 31/366 (2006.01); A61K 36/07 (2006.01);
U.S. Cl.
CPC ...
C07D 493/20 (2013.01); A61K 31/366 (2013.01); A61K 36/07 (2013.01);
Abstract

The invention relates to a novel method to isolate a natural product, a flavonoid namely inoscavin A from a Sri Lankan mushroom, medicinal preparation thereof to treat rhabdomyosarcoma cancer condition. This compound was isolated from the terrestrial basidiomycetefor the first time. The isolation method of the inoscavin A comprises the following steps of: (1) carrying out sonication extraction of pulverized specimen by methanol; (2) partitioning in to hexane, dichloromethane and ethyl acetate respectively by liquid-liquid extraction 3) fractionation using normal phase silica gel column chromatography 4) purification using preparative high performance liquid chromatography (HPLC) to obtain flavonoid compound inoscavin A in substantially purified form (≥98%). In vitro cytotoxicity experiments demonstrated that the composition comprising inoscavin A strongly induced the apoptosis of human rhabdomyosarcoma (RD) cells compared to the cytotoxicity produced on normal epithelial cells (CC-1). Therefore, isolated flavonoid compound can be used for manufacturing of a medicament to treat rhabdomyosarcoma cancer condition. A method of treating rhabdomyosarcoma using medicinal preparation comprising inoscavin A can be achieved by administering said composition to a subject in need of such treatment.


Find Patent Forward Citations

Loading…